BDSX
Biodesix Delivers Strong Q2 2026 Results, Expanding Margins and Improving Operating Leverage
Biodesix, a leading healthcare company, recently released its second-quarter results for 2026, showcasing a remarkable quarter of growth and expansion. In a call with investors, Scott Hutton, Chief Executive Officer, highlighted the company's strong performance, driven by accelerating test volume growth and improved Average Selling Prices (ASPs) in